Quest Diagnostics announced the acquisition of PhenoPath, a national provider of specialized anatomic pathology and related services. Headquartered in Seattle, WA, PhenoPath is widely recognized for its thought leadership within oncology diagnostics. PhenoPath has also developed a growing contract research business with a diverse set of biopharma clientele.
PhenoPath’s leading, specialized capabilities in molecular oncology will be leveraged across Quest’s Ameripath division. PhenoPath will also serve to strengthen Quest’s platform for growth across the Pacific Northwest.
Crosstree Capital Partners acted as exclusive financial advisor to PhenoPath. Crosstree initiated and managed a competitive process to explore a variety of strategic alternatives on behalf of PhenoPath’s owners. The transaction with Quest Diagnostics provides both liquidity for PhenoPath’s owners and a strategic partner whose vision, culture and scientific focus align well with PhenoPath.